Research Associate, Molecular & Cellular Immunology

Stylus Medicine Our Science Our Medicines Our Team Our Investors Latest News Contact Us Our Science Our Medicines Our Team Our Investors Latest News Contact Us Encoding Health Unlocking cures Developing transformative in vivo genetic medicines Developing transformative in vivo genetic medicines Developing transformative in vivo medicines Our Science Stylus Medicine is developing in vivo genetic medicines to unlock cures. Our platform is powered by engineered recombinases that encode therapeutics with high precision. Our recombinases are designed to recognize a safe harbor site in the human genome and introduce a therapeutic payload with high specificity and integrity. The features of our approach include: Our recombinases are designed to recognize a safe harbor site in the human genome and introduce a therapeutic payload with high specificity and integrity. The features of our approach include: Our recombinases are designed to recognize a safe harbor site in the human genome and introduce a therapeutic payload with high specificity and integrity. The features of our approach include: Targeted, sequence-specific introduction of therapeutic payloads Targeted, sequence-specific introduction of therapeutic payloads Targeted, sequence-specific introduction of therapeutic payloads Full-length fidelity without exposed double-stranded breaks Full-length fidelity with no exposed double-stranded breaks Reproducible, predictable and characterized insertional profile Full-length fidelity without exposed double-stranded breaks Reproducible, predictable and characterized insertional profile Reproducible, predictable and characterized insertional profile Full-length fidelity without exposed double-stranded breaks Reproducible, predictable and characterized insertional profile Capacity for large, complex, multigenic therapeutic payloads Capacity for large, complex, multigenic therapeutic payloads Capacity for large, complex, multigenic therapeutic payloads Our Medicines Our initial focus is to create in vivo CAR-T therapies. Our approach enables precise, durable CAR-T generation inside the body. These CAR-T treatments leverage a cell-targeted lipid nanoparticle (LNP) to deliver therapeutic payloads directly to immune cells in vivo. This approach has the potential to transform patient treatment, improve patient accessibility and redefine what’s possible in medicine. Elegant, therapeutic-grade recombinase: Refined to encode a durable therapeutic effect High capacity for therapeutic payloads: Capable of encoding polyfunctional multi-kb payloads Targeted lipid nanoparticle delivery: Elegant, scalable LNP-based in vivo genetic medicines Our versatile and modular approach has broad therapeutic potential across Our versatile and modular approach has broad therapeutic potential across Oncology Autoimmune Genetic Diseases and beyond Our Team Leadership Emile Nuwaysir, Ph.D. Chairman & Chief Executive Officer Jason Fontenot, Ph.D. Chief Scientific Officer Nicole Heifner SVP, Finance & Human Resources Celeste Richardson, Ph.D. SVP, Immunology Hak Chang, Ph.D., J.D. Vice President, Intellectual Property Srinivas Chollangi, Ph.D. Executive Director, CMC Tech Ops Board of Directors Emile Nuwaysir, Ph.D. Chairman & Chief Executive Officer, Stylus Medicine Nessan Bermingham, Ph.D. Operating Partner, Khosla Ventures John Gustofson President, Chugai Venture Fund Patrick Hsu, Ph.D. Co-Founder, Arc Institute, Assistant Professor of Bioengineering, the University of California, Berkeley Emily Minkow, MBA Managing Director, Venture, RA Capital Scientific Founders Patrick Hsu, Ph.D. Co-Founder, Arc Institute, Assistant Professor of Bioengineering, the University of California, Berkeley Ami S. Bhatt, M.D., Ph.D. Professor of Medicine & Genetics, Stanford University Michael C. Bassik, Ph.D. Associate Professor of Genetics, Stanford University Lacramioara Bintu, Ph.D. Associate Professor of Bioengineering, Stanford University Our Investors We are proud to be supported by leading life sciences investors and biopharmaceutical company venture funds. Latest News 7th January 2026 Stylus Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference Read More Read More September 19, 2025 The Endpoints 11: Stylus Medicine wants to usurp viral proteins and bring CAR-T to the masses Read More Read More May 13, 2025 Stylus Medicine Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting Read More Read More May 13, 2025 Stylus Medicine Launches to Develop Precision, In Vivo Genetic Medicines and Unlock the Full Potential of CAR-T Therapy Read More Read More Careers at Stylus Careers at Stylus At Stylus, our team and culture are driven by a strong commitment to advancing the science in order to improve patients' lives. We're always interested in innovative, intellectually curious and collaborative individuals to join our team . If you're excited by science and driven to make a difference, we'd love to meet you. At Stylus, our team and culture are driven by a strong commitment to advancing the science in order to improve patients' lives. We're always interested in innovative, intellectually curious and collaborative individuals to join our team . If you're excited by science and driven to make a difference, we'd love to meet you. Research Associate, Molecular & Cellular Immunology Learn More Learn More Scientist, Genome Sciences & Engineering Learn More Learn More © 2026. Stylus Medicine, Inc. 200 Technology Square, Suite 800, Cambridge, MA 02139 Stylus Medicine and the Stylus Medicine logo are registered trademarks with the U.S. Patent & Trademark Office. Terms of Use Privacy Policy © 2026. Stylus Medicine, Inc. 200 Technology Square, Suite 800, Cambridge, MA 02139 Stylus Medicine and the Stylus Medicine logo are registered trademarks with the U.S. Patent & Trademark Office. Terms of Use Privacy Policy © 2026. Stylus Medicine, Inc. 200 Technology Square, Suite 800, Cambridge, MA 02139 Stylus Medicine and the Stylus Medicine logo are registered trademarks with the U.S. Patent & Trademark Office. Terms of Use Privacy Policy